Barclays Begins Coverage on Precision BioSciences (DTIL)
Equities researchers at Barclays began coverage on shares of Precision BioSciences (NASDAQ:DTIL) in a research report issued to clients and investors on Monday, The Fly reports. The firm set an “overweight” rating on the stock.
Shares of NASDAQ DTIL opened at $12.18 on Monday. Precision BioSciences has a fifty-two week low of $12.13 and a fifty-two week high of $19.00.
In other news, Director Tony Dung Ling Yao acquired 6,487 shares of Precision BioSciences stock in a transaction on Wednesday, April 3rd. The shares were bought at an average cost of $15.42 per share, for a total transaction of $100,029.54. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Global Strategic Fund Venbio acquired 50,000 shares of Precision BioSciences stock in a transaction on Monday, April 1st. The shares were purchased at an average price of $16.00 per share, for a total transaction of $800,000.00. The disclosure for this purchase can be found here.
Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.
See Also: Is the QQQ ETF safe?
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.